Fiche traitement
Dopamine
China National Center for Cardiovascular Diseases • Insuffisance cardiaque, Maladie coronarienne
Suivi actif
Non applicable
Résumé
Dopamine est développé par China National Center for Cardiovascular Diseases. Le traitement est actuellement en Non applicable. Il est associé à Insuffisance cardiaque, Maladie coronarienne. Son objectif thérapeutique principal est Thérapie cellulaire + Traitement symptomatique. Le statut actuel est : suivi actif.
À vérifier
Thérapie cellulaire + Traitement symptomatique
Non applicable
China National Center for Cardiovascular Diseases
China
The goal of this clinical trial is to learn if intranasal umbilical cord mesenchymal stromal cell-derived exosomes (UCMSC-Exo) are safe and can help treat early Parkinson's disease in adults aged 50-75. It will also learn about the safety and tolerability of UCMSC-Exo. This is a single-center, open-label, dose-escalation study using a 3+3 design; there is no placebo and no blinding.
The main questions it aims to answer are:
1. What local and systemic adverse events and serious adverse events occur with intranasal UCMSC-Exo?
2. Does intranasal UCMSC-Exo improve motor and non-motor symptoms, biomarkers, and imaging measures in Parkinson's disease?
3. Researchers will compare low-, medium-, and high-dose UCMSC-Exo groups sequentially to assess safety and preliminary efficacy.
Participants will:
1. Receive UCMSC-Exo by nasal spray twice weekly (Monday/Thursday) for 12 weeks (24 administrations) at their assigned dose.
2. Continue their usual dopaminergic medication during the study.
3. Visit the clinic for safety assessments at weeks 4, 12, 16, and 48, and for efficacy assessments at weeks 12, 16, 24, 36, and 48.
4. Undergo blood sampling, symptom questionnaires, and PET-MR imaging at scheduled time points.
5. Be followed for a total of 48 weeks, including the 12-week treatment period and 36 weeks after treatment.
2026-10-28
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Non applicable
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Thérapie cellulaire
Traitement symptomatique
Confiance automatique : 80%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : symptom → Traitement symptomatique, mesenchymal → Thérapie cellulaire
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT07923838, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Contrôle de cohérence : 85/100
L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.
Transparence et qualité de la fiche
données vérifiablesClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-10-28
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréeNon applicable
Études associées33
Publications associées75
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
178 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2002-03-15 | Début de l’étudeNCT00024622 | Registre d’essai clinique |
| 2003-09-01 | Début de l’étudeNCT00180037 | Registre d’essai clinique |
| 2005-06-01 | Fin de l’étude prévue / enregistréeNCT00180037 | Registre d’essai clinique |
| 2006-05-23 | Début de l’étudeNCT00302146 | Registre d’essai clinique |
| 2009-02-01 | Début de l’étudeNCT00873392 | Registre d’essai clinique |
| 2009-07-01 | Début de l’étudeNCT00927108 | Registre d’essai clinique |
| 2009-10-01 | Début de l’étudeNCT00943748 | Registre d’essai clinique |
| 2011-06-01 | Début de l’étudeNCT01382342 | Registre d’essai clinique |
| 2011-10-01 | Fin de l’étude prévue / enregistréeNCT00943748 | Registre d’essai clinique |
| 2011-12-01 | Fin de l’étude prévue / enregistréeNCT00927108 | Registre d’essai clinique |
| 2012-01-24 | Début de l’étudeNCT01496599 | Registre d’essai clinique |
| 2012-09-01 | Début de l’étudeNCT01684475 | Registre d’essai clinique |
| 2013-03-13 | Début de l’étudeNCT01621581 | Registre d’essai clinique |
| 2013-04-01 | Début de l’étudeNCT01845883 | Registre d’essai clinique |
| 2013-05-01 | Fin de l’étude prévue / enregistréeNCT00873392 | Registre d’essai clinique |
| 2013-09-01 | Fin de l’étude prévue / enregistréeNCT01684475 | Registre d’essai clinique |
| 2014-02-01 | Fin de l’étude prévue / enregistréeNCT01382342 | Registre d’essai clinique |
| 2014-08-01 | Début de l’étudeNCT02492295 | Registre d’essai clinique |
| 2016-01-01 | Fin de l’étude prévue / enregistréeNCT02492295 | Registre d’essai clinique |
| 2016-12-01 | Fin de l’étude prévue / enregistréeNCT01845883 | Registre d’essai clinique |
| 2019-09-01 | Début de l’étudeNCT04046276 | Registre d’essai clinique |
| 2020-12-14 | Début de l’étudeNCT04261569 | Registre d’essai clinique |
| 2021-09-20 | Début de l’étudeNCT05142085 | Registre d’essai clinique |
| 2021-11-01 | Fin de l’étude prévue / enregistréeNCT04046276 | Registre d’essai clinique |
| 2022-02-04 | Fin de l’étude prévue / enregistréeNCT01621581 | Registre d’essai clinique |
| 2023-04-30 | Début de l’étudeNCT05799690 | Registre d’essai clinique |
| 2023-06-06 | Début de l’étudeNCT05781711 | Registre d’essai clinique |
| 2023-06-30 | Fin de l’étude prévue / enregistréeNCT05142085 | Registre d’essai clinique |
| 2023-07-12 | Début de l’étudeNCT05881460 | Registre d’essai clinique |
| 2024-08-20 | Fin de l’étude prévue / enregistréeNCT05781711 | Registre d’essai clinique |
| 2024-09-05 | Début de l’étudeNCT07838636 | Registre d’essai clinique |
| 2024-10-28 | Début de l’étudeNCT07923838 | Registre d’essai clinique |
| 2025-05-10 | Début de l’étudeNCT07001150 | Registre d’essai clinique |
| 2025-05-22 | Début de l’étudeNCT06954662 | Registre d’essai clinique |
| 2025-07-10 | Début de l’étudeNCT06964685 | Registre d’essai clinique |
| 2025-07-17 | Fin de l’étude prévue / enregistréeNCT06954662 | Registre d’essai clinique |
| 2025-08-05 | Début de l’étudeNCT07080775 | Registre d’essai clinique |
| 2026-05-06 | Début de l’étudeNCT07572903 | Registre d’essai clinique |
| 2026-05-30 | Fin de l’étude prévue / enregistréeNCT07001150 | Registre d’essai clinique |
| 2026-06-04 | Début de l’étudeNCT07682311 | Registre d’essai clinique |
| 2026-06-16 | Début de l’étudeNCT07562932 | Registre d’essai clinique |
| 2026-07-08 | Création de l’enregistrementNCT05881460 | Registre d’essai clinique |
| 2026-07-08 | Création de l’enregistrementNCT01382342 | Registre d’essai clinique |
| 2026-07-08 | PublicationCoordinated Reset Vibrotactile Stimulation Induces Sustained Cumulative Benefits in Parkinson's Disease. | Frontiers in physiology |
| 2026-07-08 | PublicationA Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease. | The Journal of pharmacology and experimental therapeutics |
| 2026-07-08 | PublicationThe Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia. | Biomolecules |
| 2026-07-08 | PublicationUnlocking the potential of lumateperone and novel anti-psychotics for schizophrenia. | BioImpacts : BI |
| 2026-07-10 | PublicationBeyond motor symptoms: efficacy of pharmacotherapies on motor, functional, and cognitive domains in Huntington's disease - a systematic review. | European journal of pharmacology |
| 2026-07-10 | PublicationElectronic structure-activity relationships of adenine-based istradefylline derivatives investigated by DFT, topological analysis, and exploratory neuronal excitability modeling. | Scientific reports |
| 2026-07-12 | Création de l’enregistrementNCT01684475 | Registre d’essai clinique |
| 2026-07-12 | PublicationDevelopments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches. | Drugs |
| 2026-07-12 | PublicationDysregulation of Human ClpP Using Small Molecules with Piperazine-Based Scaffold for Diffuse Intrinsic Pontine Glioma Therapy Validated by Patient-Derived Tumor Organoids. | Journal of medicinal chemistry |
| 2026-07-12 | PublicationState-dependent gut-brain electrophysiological coupling tracks motor complication severity in Parkinson's disease. | Bio Systems |
| 2026-07-12 | PublicationIntervention strategies for Parkinson's disease: the role of exercise and mitochondria. | Frontiers in aging neuroscience |
| 2026-07-12 | PublicationLoss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms. | EBioMedicine |
| 2026-07-13 | Dernière mise à jour du registreNCT01684475 | Registre d’essai clinique |
| 2026-07-13 | Dernière mise à jour du registreNCT05881460 | Registre d’essai clinique |
| 2026-07-13 | Dernière mise à jour du registreNCT01382342 | Registre d’essai clinique |
| 2026-07-14 | PublicationThe role of exercise intensity in motor and non-motor symptoms of Parkinson's disease: mechanisms, clinical evidence, and personalized exercise prescription parameters. | Frontiers in aging neuroscience |
| 2026-07-14 | PublicationFacilitatory effects of LY404187, a positive allosteric modulator of AMPA receptors, on swallowing initiation in anesthetized male rats. | Archives of oral biology |
| 2026-07-14 | PublicationBehavioral Effects of Renin-Angiotensin System Modulators in a Rotenone-Induced Model of Parkinson's Disease in Wistar Albino Rats. | Cureus |
| 2026-07-18 | PublicationPsilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signaling. | bioRxiv : the preprint server for biology |
| 2026-07-23 | PublicationLycopene attenuates dexamethasone induced depression like behavior and immunological dysfunction via restoration of neuro-immune-metabolic homeostasis in rats. | Scientific reports |
| 2026-07-23 | PublicationTherapeutic potential of flavonoids and rutin against inflammation-induced on a huntington animal model. | PloS one |
| 2026-08-01 | Fin de l’étude prévue / enregistréeNCT07572903 | Registre d’essai clinique |
| 2026-08-03 | Début de l’étudeNCT07741045 | Registre d’essai clinique |
| 2026-08-08 | PublicationImproving detection of low-abundant pharmaceuticals and neurotransmitters via quadrupole isolation in MALDI mass spectrometry imaging. | Analytical and bioanalytical chemistry |
| 2026-08-08 | PublicationMetoclopramide-Induced Hyperprolactinemia Mimicking Prolactinoma in a Young Woman Receiving Fragmented Care: A Case Report. | Cureus |
| 2026-08-08 | PublicationAdjunctive EGb 761 treatment in patients with Parkinson's disease: a case series. | Frontiers in aging neuroscience |
| 2026-08-08 | PublicationBasal Forebrain Volume and Concurrent Hallucinations and Mild Cognitive Impairment in Parkinson's Disease. | Movement disorders clinical practice |
| 2026-08-08 | PublicationEfficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial. | Parkinsonism & related disorders |
| 2026-08-08 | PublicationEffect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease. | Movement disorders clinical practice |
| 2026-08-08 | PublicationUltrasound-driven piezoelectric nanomaterial platform enables wireless neuromodulation for Parkinson's disease. | Acta biomaterialia |
| 2026-08-08 | PublicationReproducible Generalized Thermal Sensation Triggered by Levodopa in a Patient With Parkinson's Disease. | Journal of medical cases |
| 2026-08-08 | PublicationEffects of antidepressant administration on physical performance and perceived exertion in athletes: systematic review and meta-analysis. | International journal of clinical pharmacy |
| 2026-08-13 | Création de l’enregistrementNCT01845883 | Registre d’essai clinique |
| 2026-08-13 | Création de l’enregistrementNCT02492295 | Registre d’essai clinique |
| 2026-08-13 | Création de l’enregistrementNCT00943748 | Registre d’essai clinique |
| 2026-08-13 | Création de l’enregistrementNCT04046276 | Registre d’essai clinique |
| 2026-08-13 | Création de l’enregistrementNCT07572903 | Registre d’essai clinique |
| 2026-08-13 | Création de l’enregistrementNCT07748715 | Registre d’essai clinique |
| 2026-08-13 | Création de l’enregistrementNCT07741045 | Registre d’essai clinique |
| 2026-08-13 | Création de l’enregistrementNCT00302146 | Registre d’essai clinique |
| 2026-08-13 | Création de l’enregistrementNCT06954662 | Registre d’essai clinique |
| 2026-08-13 | Création de l’enregistrementNCT01496599 | Registre d’essai clinique |
| 2026-08-13 | PublicationInterplay of Epigenetic Reprogramming, Mitochondrial Metabolism, and Dopamine Signalling Pathways Uncovers Metabolic Vulnerabilities in Diffuse Midline Glioma. | Cancers |
| 2026-08-13 | PublicationCerebral dopamine neurotrophic factor and its functional fragments induce calcium signal through sigma-1 receptor and protect neurons against glutamate-induced excitotoxicity. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |
| 2026-08-13 | PublicationMolecular mechanisms of exercise-induced neuroprotection against Parkinson's disease. | Sports medicine and health science |
| 2026-08-13 | PublicationOral Albuterol for the Treatment of Rate-Dependent QT Prolongation and Polymorphic Ventricular Tachycardia. | JACC. Case reports |
| 2026-08-13 | PublicationEffects of pimavanserin, xanomeline and highly-purified plant-derived cannabidiol on MK-801-induced behaviours in mice relevant to psychosis. | Journal of psychopharmacology (Oxford, England) |
| 2026-08-13 | PublicationCerebellar tDCS combined with augmented reality treadmill for freezing of gait in Parkinson's disease: a randomized controlled trial. | Journal of neuroengineering and rehabilitation |
| 2026-08-13 | PublicationInsights into retention and safety/tolerability of apomorphine sublingual film in patients with Parkinson's disease and OFF episodes: post hoc analyses of a phase III, open-label study. | Therapeutic advances in neurological disorders |
| 2026-08-13 | PublicationNicotinamide Riboside Enhances Mitochondrial Bioenergetics and Dopaminergic Signaling Independent of Neuron Survival in a Double-Hit Parkinson's Model. | Research square |
| 2026-08-13 | PublicationRandomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson's disease. | Inflammopharmacology |
| 2026-08-13 | PublicationAdd-on safinamide and amantadine in Filipino Parkinson's disease patients with motor fluctuations: a retrospective exploratory cohort study. | Journal of neural transmission (Vienna, Austria : 1996) |
| 2026-08-13 | PublicationMolecular Dynamics and Electron Density Topology Reveal Ligand-Specific Interaction Patterns at the Dopamine D Receptor. | International journal of molecular sciences |
| 2026-08-13 | PublicationAn In Vivo Single-Vesicle Electrochemistry Enables Monitoring Vesicular Dopamine Dynamics and Pharmacological Rescue. | Angewandte Chemie (International ed. in English) |
| 2026-08-13 | PublicationBidirectional Mechanisms Linking Circadian Rhythm Disruption and Parkinson's Disease: Chronobiomarkers and Therapeutic Implications. | International journal of molecular sciences |
| 2026-08-16 | Création de l’enregistrementNCT05799690 | Registre d’essai clinique |
| 2026-08-16 | Création de l’enregistrementNCT05142085 | Registre d’essai clinique |
| 2026-08-16 | Création de l’enregistrementNCT00927108 | Registre d’essai clinique |
| 2026-08-16 | PublicationA mild photothermal-mediated neuroimmunomodulatory composite hydrogel reverses the inflammatory osteoclast precursor phenotype to promote osteoporotic bone defect healing. | Bioactive materials |
| 2026-08-16 | PublicationA Passiflora incarnata extract exerts multi-target effects on selected sleep-related receptors. | Journal of ethnopharmacology |
| 2026-08-16 | PublicationFlunarizine and cinnarizine in the prophylaxis of vestibular migraine and migraine-associated menière's disease: An 8-month retrospective study. | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery |
| 2026-08-16 | PublicationDopamine-modified TiCT MXene promotes supporting cell pluripotency and hair cell regeneration in cochlear organoid culture. | Biomaterials |
| 2026-08-16 | PublicationPhase I trial of hES cell-derived dopaminergic neurons for Parkinson's disease. | Nature |
| 2026-08-16 | PublicationA Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease. | Parkinson's disease |
| 2026-08-16 | PublicationDSM 17938 and Its Supernatant Ameliorate Parkinson's Disease in Association with Modulation of Gut Microbiota and Its Tryptophan Metabolism. | Antioxidants (Basel, Switzerland) |
| 2026-08-16 | PublicationThe conundrum of alpha-synuclein antibody failures in Parkinson's disease: a narrative review of mechanisms and alternative metabolic hypotheses. | Therapeutic advances in neurological disorders |
| 2026-08-16 | PublicationTherapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease. | Experimental neurology |
| 2026-08-16 | PublicationBrain Temperature Alters Contributions of Excitatory and Inhibitory Inputs to Evoked Field Potentials in the Rat Frontal Cortex. | Frontiers in cellular neuroscience |
| 2026-08-16 | PublicationCatecholaminergic neurons projecting to the paraventricular nucleus of the hypothalamus are essential for cardiorespiratory adjustments to hypoxia. | American journal of physiology. Regulatory, integrative and comparative physiology |
| 2026-08-16 | PublicationValidated chiral liquid chromatographic method for the enantiomeric separation of Pramipexole dihydrochloride monohydrate. | Journal of pharmaceutical and biomedical analysis |
| 2026-08-16 | PublicationAcamprosate reduces ethanol intake in the rat by a combined action of different drug components. | Scientific reports |
| 2026-08-16 | PublicationNigral biochemical and structural alterations following subacute exposure to MPTP in mice. | Toxicology reports |
| 2026-08-16 | PublicationA dual-channel electron expressway triggers piezocatalytic ferroptosis-mitochondrial catastrophe cascade for anti-glioblastoma therapy. | Biomaterials |
| 2026-08-16 | PublicationThe effects of unilateral carotid body excision on ventilatory control in goats. | Respiration physiology |
| 2026-08-16 | PublicationHistorical Perspectives of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. | Cold Spring Harbor perspectives in medicine |
| 2026-08-16 | PublicationPost-marketing safety of pimavanserin: a real-world pharmacovigilance study based on the FDA adverse event reporting system (FAERS). | Expert opinion on drug safety |
| 2026-08-16 | PublicationBeyond the role in motor function, entopeduncular nucleus, a critical neural hub in psychiatric disorders and sleep regulation. | Annals of medicine |
| 2026-08-16 | PublicationRecent Developments in the Drug Treatment of Parkinson's Disease. | Drugs |
| 2026-08-16 | PublicationAdvanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study. | Annals of medicine |
| 2026-08-16 | PublicationZonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. | Journal of the neurological sciences |
| 2026-08-16 | PublicationImaging of human stem cell-derived dopamine grafts correlates with behavioural recovery and reveals microstructural brain changes. | Neurobiology of disease |
| 2026-08-16 | PublicationHERV-W Envelope Triggers Abnormal Dopaminergic Neuron Process through DRD2/PP2A/AKT1/GSK3 for Schizophrenia Risk. | Viruses |
| 2026-08-16 | PublicationTherapeutic potential of astrocyte transdifferentiated neurons. | Neural regeneration research |
| 2026-08-19 | Début de l’étudeNCT07667829 | Registre d’essai clinique |
| 2026-08-26 | Création de l’enregistrementNCT00873392 | Registre d’essai clinique |
| 2026-08-26 | Création de l’enregistrementNCT00024622 | Registre d’essai clinique |
| 2026-08-26 | Création de l’enregistrementNCT01621581 | Registre d’essai clinique |
| 2026-08-26 | Dernière mise à jour du registreNCT00943748 | Registre d’essai clinique |
| 2026-09-01 | Début de l’étudeNCT07804615 | Registre d’essai clinique |
| 2026-09-01 | Publication[Treatment options for drug-induced sialorrhea: Prescribing guidelines]. | L'Encephale |
| 2026-09-01 | PublicationQuantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation. | Movement disorders : official journal of the Movement Disorder Society |
| 2026-09-11 | Création de l’enregistrementNCT07001150 | Registre d’essai clinique |
| 2026-09-11 | Création de l’enregistrementNCT07804381 | Registre d’essai clinique |
| 2026-09-11 | Création de l’enregistrementNCT07682311 | Registre d’essai clinique |
| 2026-09-11 | Création de l’enregistrementNCT07804615 | Registre d’essai clinique |
| 2026-09-11 | PublicationReversible exacerbation of parkinsonism during epirubicin-cyclophosphamide chemotherapy in a patient with PTEN hamartoma tumor syndrome and young-onset Parkinson's disease. | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology |
| 2026-09-14 | PublicationSubthalamic Nucleus Deep Brain Stimulation Enhanced Long-Latency Reflex II in Parkinson's Disease Through Rapid Subthalamic-Cortical Modulation. | Movement disorders : official journal of the Movement Disorder Society |
| 2026-09-14 | PublicationNew pharmacologic agents for insomnia and hypersomnia. | Current opinion in pulmonary medicine |
| 2026-09-20 | PublicationPharmacological treatment of cardiogenic shock. | Current opinion in critical care |
| 2026-09-27 | Création de l’enregistrementNCT07838636 | Registre d’essai clinique |
| 2026-10-01 | Début de l’étudeNCT07748715 | Registre d’essai clinique |
| 2026-10-04 | Création de l’enregistrementNCT04261569 | Registre d’essai clinique |
| 2026-10-04 | Création de l’enregistrementNCT07080775 | Registre d’essai clinique |
| 2026-10-11 | Dernière mise à jour du registreNCT00024622 | Registre d’essai clinique |
| 2026-10-11 | PublicationCarbon-coated CoNiFeCuCr high-entropy alloy nanoparticles for robust electrochemical simultaneous detection of dopamine and uric acid. | Talanta |
| 2026-10-13 | Début de l’étudeNCT07505394 | Registre d’essai clinique |
| 2026-10-18 | Création de l’enregistrementNCT07562932 | Registre d’essai clinique |
| 2026-10-18 | Création de l’enregistrementNCT07505394 | Registre d’essai clinique |
| 2026-10-18 | PublicationAmeliorative effects of half-dose saffron and chamomile combination on Psycho-endocrinological changes in a diabetic murine model. | PloS one |
| 2026-10-18 | PublicationA multimodal platform for real-time neurochemical and electrophysiologic monitoring for intraoperative neurosurgical applications. | Biosensors & bioelectronics |
| 2026-10-25 | Création de l’enregistrementNCT00180037 | Registre d’essai clinique |
| 2026-10-25 | PublicationContractile and relaxant responses of the canine isolated spinal artery to vasoactive substances. | British journal of pharmacology |
| 2026-10-25 | PublicationSubtle hypometabolism on [F]FDG-PET, yet absent [I]FP-CIT SPECT binding in a patient with spastic paraplegia type 7. | EJNMMI reports |
| 2026-10-28 | Dernière mise à jour des donnéesDopamine | Biomedical Watch |
| 2026-11-01 | Création de l’enregistrementNCT06964685 | Registre d’essai clinique |
| 2026-11-01 | Création de l’enregistrementNCT07667829 | Registre d’essai clinique |
| 2026-11-01 | Création de l’enregistrementNCT05781711 | Registre d’essai clinique |
| 2026-11-01 | Fin de l’étude prévue / enregistréeNCT05881460 | Registre d’essai clinique |
| 2026-11-08 | Création de l’enregistrementNCT07923838 | Registre d’essai clinique |
| 2026-11-08 | Dernière mise à jour du registreNCT07001150 | Registre d’essai clinique |
| 2026-12-15 | Début de l’étudeNCT07804381 | Registre d’essai clinique |
| 2027-04-28 | Fin de l’étude prévue / enregistréeNCT05799690 | Registre d’essai clinique |
| 2027-06-01 | Fin de l’étude prévue / enregistréeNCT07804615 | Registre d’essai clinique |
| 2027-06-30 | Fin de l’étude prévue / enregistréeNCT07923838 | Registre d’essai clinique |
| 2027-09-30 | Fin de l’étude prévue / enregistréeNCT07748715 | Registre d’essai clinique |
| 2028-07-01 | Fin de l’étude prévue / enregistréeNCT07080775 | Registre d’essai clinique |
| 2028-09-05 | Fin de l’étude prévue / enregistréeNCT07838636 | Registre d’essai clinique |
| 2028-10-30 | Fin de l’étude prévue / enregistréeNCT06964685 | Registre d’essai clinique |
| 2028-11-15 | Fin de l’étude prévue / enregistréeNCT07741045 | Registre d’essai clinique |
| 2029-01-31 | Fin de l’étude prévue / enregistréeNCT07667829 | Registre d’essai clinique |
| 2029-04-01 | Fin de l’étude prévue / enregistréeNCT07804381 | Registre d’essai clinique |
| 2031-10-15 | Fin de l’étude prévue / enregistréeNCT07505394 | Registre d’essai clinique |
| 2032-04-01 | Fin de l’étude prévue / enregistréeNCT04261569 | Registre d’essai clinique |
| 2032-05-01 | Fin de l’étude prévue / enregistréeNCT07682311 | Registre d’essai clinique |
| 2032-05-31 | Fin de l’étude prévue / enregistréeNCT07562932 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
33 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT07923838 | UC-MSC-Exos PD — Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease | Phase 1/2 | ACTIVE_NOT_RECRUITING | China | Shanghai Jiao Tong University School of Medicine |
| NCT06964685 | OASIS-AMICS — Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock | À vérifier | RECRUITING | United States | Abiomed Inc. |
| NCT07667829 | Vasopressor Agents in Pulmonary Hypertension Crisis | Non applicable | RECRUITING | China | China National Center for Cardiovascular Diseases |
| NCT05781711 | Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease | Phase 2 | COMPLETED | Egypt | Tanta University |
| NCT00180037 | Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease | Phase 3 | COMPLETED | Germany | Technische Universität Dresden |
| NCT07562932 | ACTION-CS — Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock | Non applicable | RECRUITING | South Korea | Chonnam National University Hospital |
| NCT07505394 | PREVENT-ICD — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease | Non applicable | RECRUITING | France | Assistance Publique - Hôpitaux de Paris |
| NCT04261569 | Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT) | Non applicable | ACTIVE_NOT_RECRUITING | France | University Hospital, Grenoble |
| NCT07080775 | The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's Disease | Phase 1/2 | ACTIVE_NOT_RECRUITING | China | XellSmart Therapeutics (Shanghai) Co., Ltd. |
| NCT07838636 | EPA-DBS — Effect of Physical Activity on the Course of Parkinson's Disease in Patients With Bilateral DBS-STN Stimulation - a Randomized Controlled Trial. | Non applicable | RECRUITING | Poland | Medical University of Warsaw |
| NCT07001150 | Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease | Phase 2 | COMPLETED | Egypt | Tanta University |
| NCT07804381 | ARREST-PD — Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease | Phase 2 | NOT_YET_RECRUITING | Non communiqué | Yonsei University |
| NCT07682311 | Auto aDBS — Automated Daytime Adaptive Deep Brain Stimulation Parameter Optimization in Patients Implanted With Percept Neurostimulator | Non applicable | RECRUITING | United States | University of California, San Francisco |
| NCT07804615 | Vista PD — A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy | Phase 2 | RECRUITING | United States, Canada | Vima Therapeutics |
| NCT00873392 | NICOPARK2 — Efficacy of Transdermal Nicotine, on Motor Symptoms in Advanced Parkinson's Disease | Phase 2 | COMPLETED | France | Assistance Publique - Hôpitaux de Paris |
| NCT00024622 | PET Scanning in Parkinson s Disease | À vérifier | COMPLETED | United States | National Institute of Mental Health (NIMH) |
| NCT01621581 | AAV2-GDNF for Advanced Parkinson s Disease | Phase 1 | COMPLETED | United States | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT05799690 | Comparison of Different Rehabilitation Protocols in Parkinson's Disease With Postural Instability and Gait Disorders | Non applicable | ACTIVE_NOT_RECRUITING | Italy | Prof. Massimo Filippi |
| NCT05142085 | Efficacy of Nano-PSO in Parkinson's Disease. | Non applicable | UNKNOWN | Mexico | Distribuidora Biolife SA de CV |
| NCT00927108 | RNASc — Rajavtihi Neuronal Adult Stem Cells Project | Phase 2 | WITHDRAWN | Thailand | Department of Medical Services Ministry of Public Health of Thailand |
| NCT01845883 | Perceptual Decision Making Under Conditions of Visual Uncertainty | Non applicable | WITHDRAWN | United States | University of California, Los Angeles |
| NCT02492295 | Low-dose Propofol for the Treatment of Severe Refractory Migraine Headache in the Emergency Department | Non applicable | TERMINATED | United States | Albert Einstein Healthcare Network |
| NCT00943748 | FAIR-PARK-I — Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's Disease | Phase 2/3 | COMPLETED | France | University Hospital, Lille |
| NCT04046276 | AEROPROTECT — Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease | Non applicable | UNKNOWN | France | Assistance Publique - Hôpitaux de Paris |
| NCT07572903 | The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease | Non applicable | COMPLETED | China | The First Affiliated Hospital of Anhui Medical University |
| NCT07748715 | B3-4D — Brain Dopamine Biomarker | À vérifier | NOT_YET_RECRUITING | Non communiqué | University of South Florida |
| NCT07741045 | Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease | Phase 3 | NOT_YET_RECRUITING | China | Hangzhou PhecdaMed Co., Ltd. |
| NCT00302146 | Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations | À vérifier | COMPLETED | United States | National Human Genome Research Institute (NHGRI) |
| NCT06954662 | A Targeted Amino Acid Supplement for People With Parkinson's Disease | Phase 1 | COMPLETED | United States | UConn Health |
| NCT01496599 | Imaging Biomarkers in Parkinson s Disease | À vérifier | COMPLETED | United States | National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT01684475 | A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE | Phase 1 | UNKNOWN | Canada | Alexandra Marine and General Hospital |
| NCT05881460 | Vibrotactile Coordinated Reset: A Non-invasive Treatment for Parkinson's Disease 2 | NA | ACTIVE_NOT_RECRUITING | United States | Synergic Medical Technologies, Inc. |
| NCT01382342 | The Effect of Rasagiline on Cognition in Parkinson's Disease | Phase 4 | COMPLETED | United States | Brown University |
Publications liées
75 publication(s)Publications liées
75 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Contractile and relaxant responses of the canine isolated spinal artery to vasoactive substances. Voir source | 1980836 | 10.1111/j.1476-5381.1990.tb12113.x | British journal of pharmacology | |
| Subtle hypometabolism on [F]FDG-PET, yet absent [I]FP-CIT SPECT binding in a patient with spastic paraplegia type 7. Voir source | 42804092 | 10.1186/s41824-026-00323-6 | EJNMMI reports | |
| Ameliorative effects of half-dose saffron and chamomile combination on Psycho-endocrinological changes in a diabetic murine model. Voir source | 36302045 | 10.1371/journal.pone.0276236 | PloS one | |
| A multimodal platform for real-time neurochemical and electrophysiologic monitoring for intraoperative neurosurgical applications. Voir source | 41161234 | 10.1016/j.bios.2025.118151 | Biosensors & bioelectronics | |
| Carbon-coated CoNiFeCuCr high-entropy alloy nanoparticles for robust electrochemical simultaneous detection of dopamine and uric acid. Voir source | 42700498 | 10.1016/j.talanta.2026.130578 | Talanta | |
| Pharmacological treatment of cardiogenic shock. Voir source | 42273963 | 10.1097/MCC.0000000000001393 | Current opinion in critical care | |
| Subthalamic Nucleus Deep Brain Stimulation Enhanced Long-Latency Reflex II in Parkinson's Disease Through Rapid Subthalamic-Cortical Modulation. Voir source | 42595494 | 10.1002/mds.70508 | Movement disorders : official journal of the Movement Disorder Society | |
| New pharmacologic agents for insomnia and hypersomnia. Voir source | 32890017 | 10.1097/MCP.0000000000000722 | Current opinion in pulmonary medicine | |
| Reversible exacerbation of parkinsonism during epirubicin-cyclophosphamide chemotherapy in a patient with PTEN hamartoma tumor syndrome and young-onset Parkinson's disease. Voir source | 42726292 | 10.1007/s10072-026-09361-1 | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | |
| [Treatment options for drug-induced sialorrhea: Prescribing guidelines]. Voir source | 35989107 | 10.1016/j.encep.2022.03.013 | L'Encephale | |
| Quantitative measurements of alternating finger tapping in Parkinson's disease correlate with UPDRS motor disability and reveal the improvement in fine motor control from medication and deep brain stimulation. Voir source | 16001401 | 10.1002/mds.20556 | Movement disorders : official journal of the Movement Disorder Society | |
| A mild photothermal-mediated neuroimmunomodulatory composite hydrogel reverses the inflammatory osteoclast precursor phenotype to promote osteoporotic bone defect healing. Voir source | 42518658 | 10.1016/j.bioactmat.2026.07.016 | Bioactive materials | |
| A Passiflora incarnata extract exerts multi-target effects on selected sleep-related receptors. Voir source | 42462921 | 10.1016/j.jep.2026.122198 | Journal of ethnopharmacology | |
| Flunarizine and cinnarizine in the prophylaxis of vestibular migraine and migraine-associated menière's disease: An 8-month retrospective study. Voir source | 42572044 | 10.1007/s00405-026-10537-w | European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery | |
| Dopamine-modified TiCT MXene promotes supporting cell pluripotency and hair cell regeneration in cochlear organoid culture. Voir source | 42229301 | 10.1016/j.biomaterials.2026.124344 | Biomaterials | |
| Phase I trial of hES cell-derived dopaminergic neurons for Parkinson's disease. Voir source | 40240592 | 10.1038/s41586-025-08845-y | Nature | |
| A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease. Voir source | 37791037 | 10.1155/2023/7427136 | Parkinson's disease | |
| DSM 17938 and Its Supernatant Ameliorate Parkinson's Disease in Association with Modulation of Gut Microbiota and Its Tryptophan Metabolism. Voir source | 42510613 | 10.3390/antiox15070882 | Antioxidants (Basel, Switzerland) | |
| The conundrum of alpha-synuclein antibody failures in Parkinson's disease: a narrative review of mechanisms and alternative metabolic hypotheses. Voir source | 42459575 | 10.1177/17562864261465665 | Therapeutic advances in neurological disorders | |
| Therapeutic properties of ayahuasca component N,N-Dimethyltryptamine in a pre-clinical model of Parkinson's disease. Voir source | 42128256 | 10.1016/j.expneurol.2026.115822 | Experimental neurology | |
| Brain Temperature Alters Contributions of Excitatory and Inhibitory Inputs to Evoked Field Potentials in the Rat Frontal Cortex. Voir source | 33364923 | 10.3389/fncel.2020.593027 | Frontiers in cellular neuroscience | |
| Catecholaminergic neurons projecting to the paraventricular nucleus of the hypothalamus are essential for cardiorespiratory adjustments to hypoxia. Voir source | 26157062 | 10.1152/ajpregu.00540.2014 | American journal of physiology. Regulatory, integrative and comparative physiology | |
| Validated chiral liquid chromatographic method for the enantiomeric separation of Pramipexole dihydrochloride monohydrate. Voir source | 16580170 | 10.1016/j.jpba.2006.02.024 | Journal of pharmaceutical and biomedical analysis | |
| Acamprosate reduces ethanol intake in the rat by a combined action of different drug components. Voir source | 37857829 | 10.1038/s41598-023-45167-3 | Scientific reports | |
| Nigral biochemical and structural alterations following subacute exposure to MPTP in mice. Voir source | 42502326 | 10.1016/j.toxrep.2026.102314 | Toxicology reports | |
| A dual-channel electron expressway triggers piezocatalytic ferroptosis-mitochondrial catastrophe cascade for anti-glioblastoma therapy. Voir source | 42114378 | 10.1016/j.biomaterials.2026.124273 | Biomaterials | |
| The effects of unilateral carotid body excision on ventilatory control in goats. Voir source | 6672918 | 10.1016/0034-5687(83)90078-6 | Respiration physiology | |
| Historical Perspectives of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. Voir source | 38858084 | 10.1101/cshperspect.a041642 | Cold Spring Harbor perspectives in medicine | |
| Post-marketing safety of pimavanserin: a real-world pharmacovigilance study based on the FDA adverse event reporting system (FAERS). Voir source | 39871820 | 10.1080/14740338.2025.2460444 | Expert opinion on drug safety | |
| Beyond the role in motor function, entopeduncular nucleus, a critical neural hub in psychiatric disorders and sleep regulation. Voir source | 42529862 | 10.1080/07853890.2026.2682576 | Annals of medicine | |
| Recent Developments in the Drug Treatment of Parkinson's Disease. Voir source | 42162439 | 10.1007/s40265-026-02327-9 | Drugs | |
| Advanced Parkinson's disease treatment patterns in Italy: results from a multicenter observational study. Voir source | 41782314 | 10.1080/07853890.2026.2628353 | Annals of medicine | |
| Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. Voir source | 30103971 | 10.1016/j.jns.2018.05.013 | Journal of the neurological sciences | |
| Imaging of human stem cell-derived dopamine grafts correlates with behavioural recovery and reveals microstructural brain changes. Voir source | 40233853 | 10.1016/j.nbd.2025.106910 | Neurobiology of disease | |
| HERV-W Envelope Triggers Abnormal Dopaminergic Neuron Process through DRD2/PP2A/AKT1/GSK3 for Schizophrenia Risk. Voir source | 35062349 | 10.3390/v14010145 | Viruses | |
| Therapeutic potential of astrocyte transdifferentiated neurons. Voir source | 41467429 | 10.4103/NRR.NRR-D-25-00554 | Neural regeneration research | |
| Interplay of Epigenetic Reprogramming, Mitochondrial Metabolism, and Dopamine Signalling Pathways Uncovers Metabolic Vulnerabilities in Diffuse Midline Glioma. Voir source | 42512251 | 10.3390/cancers18142186 | Cancers | |
| Cerebral dopamine neurotrophic factor and its functional fragments induce calcium signal through sigma-1 receptor and protect neurons against glutamate-induced excitotoxicity. Voir source | 41604891 | 10.1016/j.biopha.2026.119034 | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie | |
| Molecular mechanisms of exercise-induced neuroprotection against Parkinson's disease. Voir source | 41646181 | 10.1016/j.smhs.2025.05.004 | Sports medicine and health science | |
| Oral Albuterol for the Treatment of Rate-Dependent QT Prolongation and Polymorphic Ventricular Tachycardia. Voir source | 42559783 | 10.1016/j.jaccas.2026.109448 | JACC. Case reports | |
| Effects of pimavanserin, xanomeline and highly-purified plant-derived cannabidiol on MK-801-induced behaviours in mice relevant to psychosis. Voir source | 42345506 | 10.1177/02698811261456216 | Journal of psychopharmacology (Oxford, England) | |
| Cerebellar tDCS combined with augmented reality treadmill for freezing of gait in Parkinson's disease: a randomized controlled trial. Voir source | 39342307 | 10.1186/s12984-024-01457-z | Journal of neuroengineering and rehabilitation | |
| Insights into retention and safety/tolerability of apomorphine sublingual film in patients with Parkinson's disease and OFF episodes: post hoc analyses of a phase III, open-label study. Voir source | 40547865 | 10.1177/17562864251343583 | Therapeutic advances in neurological disorders | |
| Nicotinamide Riboside Enhances Mitochondrial Bioenergetics and Dopaminergic Signaling Independent of Neuron Survival in a Double-Hit Parkinson's Model. Voir source | 42370283 | 10.21203/rs.3.rs-9970859/v1 | Research square | |
| Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson's disease. Voir source | 40434674 | 10.1007/s10787-025-01752-8 | Inflammopharmacology | |
| Add-on safinamide and amantadine in Filipino Parkinson's disease patients with motor fluctuations: a retrospective exploratory cohort study. Voir source | 42550256 | 10.1007/s00702-026-03246-5 | Journal of neural transmission (Vienna, Austria : 1996) | |
| Molecular Dynamics and Electron Density Topology Reveal Ligand-Specific Interaction Patterns at the Dopamine D Receptor. Voir source | 42589229 | 10.3390/ijms27156572 | International journal of molecular sciences | |
| An In Vivo Single-Vesicle Electrochemistry Enables Monitoring Vesicular Dopamine Dynamics and Pharmacological Rescue. Voir source | 42585093 | 10.1002/anie.6461178 | Angewandte Chemie (International ed. in English) | |
| Bidirectional Mechanisms Linking Circadian Rhythm Disruption and Parkinson's Disease: Chronobiomarkers and Therapeutic Implications. Voir source | 42589377 | 10.3390/ijms27156719 | International journal of molecular sciences | |
| Improving detection of low-abundant pharmaceuticals and neurotransmitters via quadrupole isolation in MALDI mass spectrometry imaging. Voir source | 42448886 | 10.1007/s00216-026-06659-z | Analytical and bioanalytical chemistry | |
| Metoclopramide-Induced Hyperprolactinemia Mimicking Prolactinoma in a Young Woman Receiving Fragmented Care: A Case Report. Voir source | 42549416 | 10.7759/cureus.112043 | Cureus | |
| Adjunctive EGb 761 treatment in patients with Parkinson's disease: a case series. Voir source | 42539673 | 10.3389/fnagi.2026.1767148 | Frontiers in aging neuroscience | |
| Basal Forebrain Volume and Concurrent Hallucinations and Mild Cognitive Impairment in Parkinson's Disease. Voir source | 41144884 | 10.1002/mdc3.70413 | Movement disorders clinical practice | |
| Efficacy of citicoline as an add-on therapy in Parkinson's disease: a randomized, double-blind trial. Voir source | 42561742 | 10.1016/j.parkreldis.2026.108911 | Parkinsonism & related disorders | |
| Effect of COMT and UGT1A Variants on Clinical Response to Opicapone in Parkinson's Disease. Voir source | 42473901 | 10.1002/mdc3.70751 | Movement disorders clinical practice | |
| Ultrasound-driven piezoelectric nanomaterial platform enables wireless neuromodulation for Parkinson's disease. Voir source | 42419549 | 10.1016/j.actbio.2026.07.010 | Acta biomaterialia | |
| Reproducible Generalized Thermal Sensation Triggered by Levodopa in a Patient With Parkinson's Disease. Voir source | 42564325 | 10.14740/jmc5357 | Journal of medical cases | |
| Effects of antidepressant administration on physical performance and perceived exertion in athletes: systematic review and meta-analysis. Voir source | 42560424 | 10.1007/s11096-026-02206-z | International journal of clinical pharmacy | |
| Lycopene attenuates dexamethasone induced depression like behavior and immunological dysfunction via restoration of neuro-immune-metabolic homeostasis in rats. Voir source | 42472869 | 10.1038/s41598-026-62143-9 | Scientific reports | |
| Therapeutic potential of flavonoids and rutin against inflammation-induced on a huntington animal model. Voir source | 42461930 | 10.1371/journal.pone.0339016 | PloS one | |
| Psilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signaling. Voir source | 42465498 | 10.64898/2026.07.05.736652 | bioRxiv : the preprint server for biology | |
| The role of exercise intensity in motor and non-motor symptoms of Parkinson's disease: mechanisms, clinical evidence, and personalized exercise prescription parameters. Voir source | 42444985 | 10.3389/fnagi.2026.1831208 | Frontiers in aging neuroscience | |
| Facilitatory effects of LY404187, a positive allosteric modulator of AMPA receptors, on swallowing initiation in anesthetized male rats. Voir source | 42314242 | 10.1016/j.archoralbio.2026.106665 | Archives of oral biology | |
| Behavioral Effects of Renin-Angiotensin System Modulators in a Rotenone-Induced Model of Parkinson's Disease in Wistar Albino Rats. Voir source | 42317891 | 10.7759/cureus.109052 | Cureus | |
| Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches. Voir source | 41964795 | 10.1007/s40265-026-02312-2 | Drugs | |
| Dysregulation of Human ClpP Using Small Molecules with Piperazine-Based Scaffold for Diffuse Intrinsic Pontine Glioma Therapy Validated by Patient-Derived Tumor Organoids. Voir source | 42418817 | 10.1021/acs.jmedchem.6c00777 | Journal of medicinal chemistry | |
| State-dependent gut-brain electrophysiological coupling tracks motor complication severity in Parkinson's disease. Voir source | 42203101 | 10.1016/j.biosystems.2026.105835 | Bio Systems | |
| Intervention strategies for Parkinson's disease: the role of exercise and mitochondria. Voir source | 40438505 | 10.3389/fnagi.2025.1519672 | Frontiers in aging neuroscience | |
| Loss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms. Voir source | 42431745 | 10.1016/j.ebiom.2026.106339 | EBioMedicine | |
| Beyond motor symptoms: efficacy of pharmacotherapies on motor, functional, and cognitive domains in Huntington's disease - a systematic review. Voir source | 42162688 | 10.1016/j.ejphar.2026.178993 | European journal of pharmacology | |
| Electronic structure-activity relationships of adenine-based istradefylline derivatives investigated by DFT, topological analysis, and exploratory neuronal excitability modeling. Voir source | 42350597 | 10.1038/s41598-026-60070-3 | Scientific reports | |
| Coordinated Reset Vibrotactile Stimulation Induces Sustained Cumulative Benefits in Parkinson's Disease. Voir source | 33889086 | 10.3389/fphys.2021.624317 | Frontiers in physiology | |
| A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease. Voir source | 35110393 | 10.1124/jpet.121.000842 | The Journal of pharmacology and experimental therapeutics | |
| The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia. Voir source | 37627285 | 10.3390/biom13081220 | Biomolecules | |
| Unlocking the potential of lumateperone and novel anti-psychotics for schizophrenia. Voir source | 40161932 | 10.34172/bi.30259 | BioImpacts : BI |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-10-28
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.